Siludi Pharmaceutical Co., Ltd. (01244) announced interim results. Shareholders' losses were 103.5 million yuan, a year-on-year decrease of 42%

Zhitongcaijing · 08/30 14:25

According to the Zhitong Finance App, Siludi Pharmaceutical Co., Ltd. (01244) announced results for the six months ended June 30, 2024, with revenue of 206 million yuan (RMB, same below), a year-on-year decrease of 41.4%; loss attributable to parent company owners was 103.5 million yuan, a year-on-year decrease of 42%; and a basic loss of 0.42 yuan per share.

During the reporting period, all of the company's revenue came from sales of the commercialized product Envida® (Envolimab, subcutaneous PD-L1 inhibitor) by directly cooperating distributors. The main reason for the decline in revenue during the period was Envida® product sales approval and commercialization at the end of November 2021. The decline in revenue is a result of intense competition in the PD-1/L1 market in 2024.